Typically, this means the cases share a common defendant, a common product, and substantially similar allegations
If you are experiencing hair loss while taking weight-loss injections, you are not alone, and you should know that this type of shedding is almost always temporary
July 2, 2024
At a glance Retatrutide is an investigational weekly injection from Eli Lilly, not yet licensed in the UK It targets three hormone receptors at once GLP-1, GIP and glucagon earning it the nickname "triple G" It reduces appetite, improves blood sugar, and appears to nudge resting energy expenditure upwards Phase 2 trial participants lost an average of around 24% of body weight over 48 weeks at the top dose Side effects mirror existing GLP-1 medications: nausea, mild gut symptoms, reduced appetite Expected UK approval is 18-24 months away pending Phase 3 results and MHRA review The basics: what retatrutide is Retatrutide is an investigational weekly injection being developed by Eli Lilly for weight loss and related metabolic conditions
Clinical review: Treatment of pediatric obesity: A systematic review and meta-analysis of randomized trials
Nothing in the book is actually new, he admits, just a more digestible version of his previous 640-page "Good Calories, Bad Calories" tome and several magazine articles he wrote on the virtues of ridding our diets of fattening carbohydrates
